1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Grit Biotechnology Receives U.S. FDA Clearance of IND Application for GT201

03 Sep 2024
Admin
News Article

Grit Biotechnology Receives U.S. FDA Clearance of IND Application for GT201

Grit Biotechnology Receives U.S. FDA Clearance of Investigational New Drug Application for GT201, a genetically engineered TIL, following its Chinese IND Approval

Overview

Grit Biotechnology, a leading clinical-stage cell therapy company focusing on tumor-infiltrating lymphocyte (TIL) therapies, has achieved a major milestone with its genetically engineered TIL product, GT201. Following its investigational new drug (IND) approval in China in July 2023, GT201 has now also received IND clearance from the U.S. FDA, paving the way for clinical trials in the United States.

About GT201

GT201, an advanced genetically engineered TIL product developed by Grit Biotechnology's platform StemTexp® and StaViral®, boosts T cell survival and function by expressing a vital membrane-bound cytokine complex.
GT201 surpasses traditional TIL therapies in proliferation, tumor-killing efficacy and long-term survival with reduced dependence on IL-2.
Now, GT201 IND is approved by both U.S. FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for advanced solid tumor patients.

About the Company: Grit Biotechnology

Grit Biotechnology is a clinical stage cell therapy company leading TIL therapy development based in China.
Core technology platforms supporting its TIL and other cell therapy development include StemTexp® (proprietary stemness TIL expansion platform), StaViral® (stable virus transduction system), KOReTIL® (efficient CRISPR KO system) and ImmuT Finder® (genome-wide CRISPR/Cas screening platform).
These platforms have enabled the development of next-generation gene-edited TIL products and other cell therapies.

In addition, Grit's non-gene-engineered TIL program, GT101, is currently in Phase 2 (pivotal) trials and is on track to file for Biologics License Application (BLA) in 2025, making it the leading TIL pipeline in China.